The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing

Society for Clinical Trials 37th Annual Meeting
May 18, 2016

Joseph S. Ross, MD, MHS
Section of General Internal Medicine, School of Medicine
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Open Data, Open Science – Why?

Underreporting Research Is Scientific Misconduct

Iain Chalmers, FRCOG

Substantial numbers of clinical trials are never reported in print, and among those that are, many are not reported in sufficient detail to enable judgments to be made about the validity of their results. Failure to publish an adequate account of a well-designed clinical trial is a form of scientific misconduct that can lead those caring for patients to make inappropriate treatment decisions. Investigators, research ethics committees, funding bodies, and scientific editors all have responsibilities to reduce underreporting of clinical trials. An extended use of prospective registration of trials at inception, as well as benefiting clinical research in other ways, could help people to play their respective roles in reducing underreporting of clinical trials.

Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis

• Trials registered at CT.gov in 2000 onwards, completed as of June 2007 (≥ 2 years for all)
• 46% of trials published

<table>
<thead>
<tr>
<th>Trial Funder</th>
<th>Publication, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry</td>
<td>40</td>
</tr>
<tr>
<td>Non-government / Non-industry</td>
<td>56</td>
</tr>
<tr>
<td>Government (US and non-US)</td>
<td></td>
</tr>
<tr>
<td>US NIH</td>
<td>41</td>
</tr>
<tr>
<td>non-NIH, US Government</td>
<td>56</td>
</tr>
<tr>
<td>non-US Government</td>
<td>57</td>
</tr>
</tbody>
</table>

• ~50% of clinical trials are never published

• Even when published, limited portion of collected data is reported
  – Particularly safety details

• Patients and physicians frequently make treatment decisions based on a fraction of potentially available clinical data

Why Share Data?

• Promotes data transparency, potential to lead to better informed clinical decisions
• Positions research as a public good
• Respects contributions of participants:
  – maximizing value of collected data, while
  – minimizing duplicative data collection
• Facilitates secondary studies of existing data
• Promotes reproducibility:
  – sample, design, and analysis
Somewhere, something incredible is waiting to be known. - Carl Sagan
Principles of the YODA Project

• Promote sharing of clinical research data to advance science and improve public health and healthcare
• Promote responsible conduct of research
• Ensure good stewardship of clinical research data by external investigators
• Protect rights of research participants
Johnson & Johnson Partnership

• Focused on providing access to clinical trial data:
  – All pharmaceutical products (including historical)
  – Device and diagnostic products from 2014 onward

• Prepared data access policy and established clear procedures with input from Steering Cmte, experts, stakeholders, and public comment

• Require application, registration, public reporting, publication

• YODA Project website provides info on trial and supporting documentation
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

PRODUCT INFO
- Generic Name: Abiraterone acetate
- Product Name: ZYTiga™
- Therapeutic Area: Cancers and Other Neoplasms
- Enrollment: 1,185

SUPPORTING DOCUMENTATION
- Analysis Datasets
- Annotated Case Report Form (CRF)
- Clinical Study Report
- Collected Datasets
- Data Definition Specification
- Protocol with Amendments
- Statistical Analysis Plan

APPROVED DATA REQUESTS ASSOCIATED WITH THIS TRIAL
### Inquiries Submitted

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total inquiries, No.</td>
<td>52</td>
</tr>
<tr>
<td>Inquiry led to full data request, No. (%)</td>
<td>6 (13%)</td>
</tr>
<tr>
<td>Total unique trials requested within inquiries, No.</td>
<td>104</td>
</tr>
<tr>
<td>Trial data can be made “available”, No. (%)</td>
<td>66 (64%)</td>
</tr>
<tr>
<td>Trial data cannot be made “available”, No. (%)</td>
<td>38 (37%)</td>
</tr>
</tbody>
</table>
• Investigator name, affiliation, co-investigators
• Research proposal, including background, study design, main outcomes, statistical analysis plan
• COI statement
• Once approved, require signed DUA
• Investigators gain access to data maintained on secure platform, via VPN
• Prevents distribution, protects patient privacy
• Public reporting of approved requests, submitted proposals, results of project
Somewhere, something incredible is waiting to be known. - Carl Sagan
This section of the site provides information on study sponsor’s criteria for listing studies and other relevant sponsor specific information.

Select the sponsor’s logo to view this information.
How YODA Project is Different

• Not our data

• Independent third party without interests, removing perception of influence over access

• YODA Project has full jurisdiction to make decisions regarding data access

• Policies and procedures established via public comment in the best interests of:
  – Scientific profession and investigators
  – Patients and research subjects
  – Data Holders / Partners
“Stakeholders should foster a culture in which data sharing is the expected norm, and should commit to responsible strategies aimed at maximizing benefits, minimizing risks, and overcoming challenges of sharing trial data”

Source: Institute of Medicine report, January 2015.
Micro Challenges Ahead

• Creating a platform that facilitates research
  – What trials are or can be made available?
  – What meta-data are needed: CRFs, protocol, SAPs?
• Engaging research community to use data
• Resources are not unlimited – fee?
• Patient privacy, secure data analytic platform – how easy can it be?
• Maintaining public input, transparency
• Scope and intensity of review
• Data Use Agreements
Macro Challenges Ahead

• Large pharmaceutical companies far ahead
  – What about mid-size, small biotech?
  – What about medical device companies?
  – What about academics?

• Linking data sharing platforms

• Dream of automated meta-analyses – will we ever get there?
Objectives Remain Clear

• Facilitate greater access to clinical trial data, increasing transparency and accelerating generation of new knowledge, while promoting responsible conduct of research

• Better inform patients, clinicians, and industry so that decisions can be based on the most comprehensive and contemporary evidence available relevant to benefits and harms of therapies
http://yoda.yale.edu

joseph.ross@yale.edu